StreetInsider.com News Articles

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

Fri, 11 Sep 2026 10:20:00 -0400

si-local-file:///var/storage/secattach/20260911/27051510.html

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Access the video webcast here

IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

The presentation, featuring Robert Berman, Chief Executive Officer of enVVeno Medical, provides an overview of the Company and its innovative enVVe® System, as well as recent corporate and clinical developments.

The on-demand presentation is available for viewing beginning today, September 11, 2026,

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Access the video webcast here

The on-demand presentation is available for viewing beginning today, September 11, 2026,

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video Webcast Now Available Here

IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference.

For the event, Mr. Berman highlighted the Company's investment opportunity, including the significant unmet need for effective treatment options for patients with severe Deep Venous Insufficiency (DVI) and the substantial market opportunity for Company's non-surgical replacement venous

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video Webcast Now Available Here

enVVeno Medical (NVNO) files $100M mixed shelf

Fri, 21 Aug 2026 16:36:26 -0400

enVVeno Medical (NASDAQ: NVNO) filed $100,000,000 mixed shelf of:

COMMON STOCK

PREFERRED STOCK

PURCHASE CONTRACTS

WARRANTS

SUBSCRIPTION RIGHTS

DEPOSITARY SHARES

DEBT SECURITIES

UNITS

enVVeno Medical (NVNO) files $100M mixed shelf

Fri, 21 Aug 2026 16:36:26 -0400

enVVeno Medical (NASDAQ: NVNO) filed $100,000,000 mixed shelf of:

COMMON STOCK

PREFERRED STOCK

PURCHASE CONTRACTS

WARRANTS

SUBSCRIPTION RIGHTS

DEPOSITARY SHARES

DEBT SECURITIES

UNITS

Form S-3 enVVeno Medical Corp

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961806.html

Form S-3 enVVeno Medical Corp

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961806.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932855.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932855.html

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatm

Tue, 04 Aug 2026 08:46:00 -0400

Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage determinations and reimbursement policies for enVVeno Medical's enVVe non-surgical replacement venous valve

Publication Highlights:

Peer-reviewed publication in the Journal of Vascular Surgery: Venous and Lymphatic Disorders
More than $32,000 projected healthcare savings per patient over five years
Approximately 2.2 fewer venous ulcers per patient compared to standard of care
Approximately $4,100 projected cost savings per each rVCSS* point of clinical improvement
Economically dominant versus compression therapy and

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatm

Tue, 04 Aug 2026 08:46:00 -0400

Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage determinations and reimbursement policies for enVVeno Medical's enVVe non-surgical replacement venous valve
Publication Highlights:
Peer-reviewed publication in the Journal of Vascular Surgery: Venous and Lymphatic Disorders
More than $32,000 projected healthcare savings per patient over five years
Approximately 2.2 fewer venous ulcers per patient compared to standard of care
Approximately $4,100 projected cost savings per each rVCSS* point of clinical improvement
Economically dominant versus compression therapy and

enVVeno Medical (NVNO) Misses Q2 EPS by 537c

Fri, 31 Jul 2026 09:19:19 -0400

enVVeno Medical (NASDAQ: NVNO) reported Q2 EPS of ($5.37).
For earnings history and earnings-related data on enVVeno Medical (NVNO) click here.

enVVeno Medical posts Q2 2026 results, gets FDA nod for venous valve trial

Fri, 31 Jul 2026 08:31:51 -0400

enVVeno Medical Corporation (NASDAQ: NVNO) reported its second quarter 2026 financial results and disclosed that it received U.S. Food and Drug Administration Investigational Device Exemption (IDE) approval to begin a pivotal trial for its enVVe System, a minimally invasive replacement venous valve designed for patients with severe deep chronic venous insufficiency.
The company recorded a net loss of $3.6 million, or $5.37 per basic and diluted share, for the quarter ended June 30, 2026, compared to a net loss of $6.7 million, or $11.52 per basic and diluted share, for the same period in 2025.
As of June 30, 2026, enVVeno Medical

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

Fri, 31 Jul 2026 08:30:00 -0400

Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027

IRVINE, CA / ACCESS Newswire / July 31, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the second quarter ended June 30, 2026, and highlighted by the significant regulatory milestone of receiving U.S. Food and Drug Administration (FDA) IDE approval to begin the

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

Fri, 31 Jul 2026 08:30:00 -0400

Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027

IRVINE, CA / ACCESS Newswire / July 31, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the second quarter ended June 30, 2026, and highlighted by the significant regulatory milestone of receiving U.S. Food and Drug Administration (FDA) IDE approval to begin the

Form 10-Q enVVeno Medical Corp For: Jun 30

Thu, 30 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260730/26843542.html

Form 10-Q enVVeno Medical Corp For: Jun 30

Thu, 30 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260730/26843542.html

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Wed, 15 Jul 2026 08:30:00 -0400

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market
Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / July 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.
As part of the segment, Mr. Berman discussed the Company's recent news announcing the issuance of the first U.S.

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Wed, 15 Jul 2026 08:30:00 -0400

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market
Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / July 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.
As part of the segment, Mr. Berman discussed the Company's recent news announcing the issuance of the first U.S.

Form 8-K enVVeno Medical Corp For: Jul 14

Tue, 14 Jul 2026 16:56:00 -0400
si-local-file:///var/storage/secattach/20260714/26768889.html

Form 8-K enVVeno Medical Corp For: Jul 14

Tue, 14 Jul 2026 16:56:00 -0400
si-local-file:///var/storage/secattach/20260714/26768889.html

enVVeno Medical receives first U.S. patent for venous valve system

Tue, 07 Jul 2026 08:29:14 -0400

enVVeno Medical Corporation (NASDAQ: NVNO) announced the issuance of U.S. Patent No. 12,575,932, covering key components of its enVVe transcatheter replacement venous valve system, according to a company press release.

The patent covers the enVVe valve, valve support frame, crimping system, and delivery system, as well as methods for treating patients with deep venous insufficiency (DVI), a condition caused by damaged venous valves that can lead to reflux, venous hypertension, and venous leg ulcers.

The enVVe system is designed as a catheter-based, non-surgical alternative to open surgical venous valve replacement. The company states the system is intended to eliminate the need for

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

Tue, 07 Jul 2026 08:29:00 -0400

New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve
Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market Opportunity
enVVe Pivotal Study on Track for Enrollment to Commence and First Patients Data Release Expected by the End of Q4 2026

IRVINE, CA / ACCESS Newswire / July 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe® transcatheter replacement venous valve system for